NeuroOne (NMTC) director receives new RSU and stock option grants

Rhea-AI Filing Summary

NeuroOne Medical Technologies board member Edward Andrle reported receiving new equity awards. He was granted an option to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments over one year.

He also received 41,929 restricted stock units that vest in 12 equal monthly installments over the same one-year period, with vesting at each month-end. Following the stock grant, Andrle directly holds 133,932 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Andrle Edward

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	26,036	$0.00	--
Grant/Award	Common Stock	41,929	$0.00	--

Holdings After Transaction: Option to Purchase Common Stock — 26,036 shares (Direct); Common Stock — 133,932 shares (Direct)

Footnotes (1)

1. Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.

Key Figures

Option grant size: 26,036 options Option exercise price: $0.795 per share Option expiration: April 2, 2036 +3 more

6 metrics

Option grant size 26,036 options Option to purchase common stock granted to director Andrle

Option exercise price $0.795 per share Exercise price for 26,036 stock options

Option expiration April 2, 2036 Expiration date of Andrle’s stock option grant

RSU grant size 41,929 RSUs Restricted stock units granted, vesting monthly over one year

Post-grant share holdings 133,932 shares Common shares directly held after RSU grant

Vesting schedule 12 equal monthly installments Applies to both RSUs and stock option grant

Key Terms

restricted stock units, Option to Purchase Common Stock, vests in 12 equal monthly installments, grant, award, or other acquisition

4 terms

restricted stock units financial

"Represents a grant of restricted stock units, which vest in 12 equal monthly installments"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Option to Purchase Common Stock financial

"security_title: Option to Purchase Common Stock"

vests in 12 equal monthly installments financial

"The option vests in 12 equal monthly installments over a one-year period"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrle Edward

(Last) (First) (Middle)

C/O NEUROONE MEDICAL TECHNOLOGIES CORP

7599 ANAGRAM DRIVE

(Street)

EDEN PRAIRIE MINNESOTA 55344

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/03/2026		A		41,929(1)	A	$0	133,932	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.795	04/03/2026		A		26,036		(2)	04/02/2036	Common Stock	26,036	$0	26,036	D

Explanation of Responses:

1. Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.

2. The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.

	/s/ Emily Johns, by Power of Attorney	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did NMTC director Edward Andrle report?

Edward Andrle reported receiving equity awards, not open-market trades. He was granted 26,036 stock options and 41,929 restricted stock units, both vesting monthly over one year. These awards increase his direct equity exposure to NeuroOne Medical Technologies.

How many NMTC stock options were granted to Edward Andrle?

Edward Andrle was granted an option to purchase 26,036 shares of NeuroOne common stock. The option has an exercise price of $0.795 per share, vests in 12 equal monthly installments over one year, and expires on April 2, 2036 if not exercised.

What are the details of the restricted stock units granted to NMTC’s director?

Andrle received 41,929 restricted stock units of NeuroOne common stock. These RSUs vest in 12 equal monthly installments over a one-year period, with each installment vesting at the end of the month, aligning ongoing service with incremental share delivery.

How did these equity grants change Edward Andrle’s NMTC share holdings?

After the reported stock grant, Edward Andrle directly holds 133,932 shares of NeuroOne common stock. This figure reflects his direct non-derivative holdings following the 41,929-share restricted stock award disclosed in the Form 4 insider transaction report.

When do Edward Andrle’s newly granted NMTC stock options expire?

The stock options granted to Edward Andrle expire on April 2, 2036. They have an exercise price of $0.795 per share and vest in 12 equal monthly installments over one year, providing a long-dated potential ownership opportunity once vested and exercised.

Are Edward Andrle’s NMTC equity awards immediate or time-vested?

Both the restricted stock units and the option grant are time-vested. Each award vests in 12 equal monthly installments over a one-year period, with vesting occurring at the end of each month rather than all shares becoming available immediately.